Medicamen Organ.

- Currently, Medicamen Organics Limited is funding all its expansion through internal accruals. - There are no immediate plans for generating funds through debt or equity. - The company has raised INR 3 crores via issuing and allotting 4,65,910 convertible warrants on a preferential basis to the Promoter Group to strengthen working capital without affecting the existing financial structure. - For the Nepal facility investment, the company plans to invest around INR 9 crores as its portion of capital, which will be funded internally. - No explicit mention of future fundraising through debt or equity was made; the focus remains on internal accrual funding and controlled investments.

- INR9 crores investment planned to acquire 30% stake in Medi Hub Organic Limited, Nepal, through subsidiary Grande Etoile Pharmaceuticals Limited. - Expansion of Haridwar manufacturing facility by 20% underway to enhance operational efficiency and scale production. - Plans to construct an EU-approved manufacturing facility for better control over production, targeted commercialization starting around 15 months from now, with first-year revenue potential of INR50 crores. - No current plans for fundraising; expansions funded through internal accruals and INR3 crores raised via convertible warrants from Promoter Group. - The Nepal facility represents a strategic investment to enter new markets and meet European quality standards, supplementing capacity and global footprint. - Future plan includes possible manufacturing facility in Africa in 2-3 years to access new markets.

- Medicamen Organics targets revenues of INR 60-65 crores for FY '26. - The company plans a 60% CAGR in revenue over the next three years. - Expansion includes a 20% capacity increase at the Haridwar facility. - Nepal facility expected to contribute from FY '27 onwards, with optimum potential above INR 400 crores. - Focus on growing export markets, aiming for 75% export and 25% domestic revenue mix. - Plans to register around 120 products in Africa over the next two years. - Growth driven by diversification into personal care/cosmetics with INR 15 crores revenue targeted for FY '26. - Expansion into better, more profitable markets like Latin America and Europe through associate manufacturing. - Anticipated rise in volumes supported by capacity additions and geographic market expansion.

- Medicamen Organics Limited targets **60% CAGR revenue growth** over the next three years. - For FY '26, projected revenue is around **INR 60-65 crores**. - EBITDA margins expected around **24%**, considering new segments like cosmetics and personal care. - Profit After Tax (PAT) aims to be maintained at or above **10%**. - Growth drivers include expansion into new markets such as East Africa, Nepal, and Europe, with 120 product registrations planned. - Margins are currently around 17%, expected to improve as marketing investments stabilize and focus shifts to profitable products. - Optimum utilization of existing capacity is 60-65%, with a planned **20% capacity expansion** to support growth. - Nepal facility to contribute significantly after commercialization, with potential revenues exceeding **INR 400 crores** at full optimal utilization. - EPS expected to improve in line with revenue and profitability growth, supported by internal accrual funding and no immediate dividend payout to reinvest in expansion.

- Current orders in hand with the East Africa subsidiary stand at around $125,000. - An advance payment of $50,000 has been received from the subsidiary. - The first shipment from the East Africa operations is scheduled for this month. - Post initial shipment, similar subsequent orders are expected. - The company is preparing for a good influx of orders this year, supported by 20% capacity expansion at the primary facility. - Focus on markets like Latin America (Mexico, Brazil), Europe, and Francophone Africa is expected to drive order growth. - The company is also targeting registrations of around 120 products over the next two years, which should contribute significantly to revenues from FY '26 onwards.